Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Storer, R. D.
Right arrow Articles by Soper, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Storer, R. D.
Right arrow Articles by Soper, K. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 29, No. 1 suppl, 30-50 (2001)
DOI: 10.1080/019262301753178465

p53 +/- Hemizygous Knockout Mouse: Overview of Available Data

Richard D. Storer

Merck & Co Inc, West Point, Pennsylvania 19486, richardstorer{at}merck.com

John E. French

National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

Joseph Haseman

National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709

Gerald Hajian

Schering Plough Research Institute, Kenilworth, New Jersey 07083

Edmund K. Legrand

RW Johnson Pharmaceutical Research Institute, Raritan New Jersey 08869

Gerald G. Long

Eli Lilly & Co, Greenfield, Indiana 46140

Lori A. Mixson

Merck & Co Inc, West Point, Pennsylvania 19486

Ricardo Ochoa

Pfizer, Inc, Groton, Connecticut 06340

John E. Sagartz

Monsanto, St. Louis, MO 63141

Keith A. Soper

Merck & Co Inc, West Point, Pennsylvania 19486

The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17β-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-defi cient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed.

Key Words: p53 deficient • bioassay • short-term • 26-weeks • alternatives • carcinogenicity • testing.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams
Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals
Toxicol Pathol, December 1, 2006; 34(7): 827 - 852.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
P. A. McAnulty and M. Skydsgaard
Diethylstilbestrol (DES): Carcinogenic Potential in Xpa-/-, Xpa-/-/p53+/-, and Wild-Type Mice During 9 Months' Dietary Exposure
Toxicol Pathol, August 1, 2005; 33(5): 609 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. M. Elrick, J. A. Kramer, C. L. Alden, E. A. G. Blomme, R. T. Bunch, M. A. Cabonce, S. W. Curtiss, L. D. Kier, K. L. Kolaja, C. P. Rodi, et al.
Differential Display in Rat Livers Treated for 13 Weeks with Phenobarbital Implicates a Role for Metabolic and Oxidative Stress in Nongenotoxic Carcinogenicity
Toxicol Pathol, January 1, 2005; 33(1): 118 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
B. A.R. Lina, R. A. Woutersen, J. P. Bruijntjes, J. Van Benthem, J. A.H. Van Den Berg, J. Monbaliu, B. J.J.M. Thoolen, R. B. Beems, and C. F. Van Kreijl
Evaluation of the Xpa-Deficient Transgenic Mouse Model for Short-Term Carcinogenicity Testing: 9-Month Studies with Haloperidol, Reserpine, Phenacetin, and D-Mannitol
Toxicol Pathol, February 1, 2004; 32(2): 192 - 201.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment Statement on ILSI/HESI Research Programme on Alternative Cancer Models
Toxicol Pathol, February 1, 2003; 31(2): 254 - 257.
[PDF]